Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease

PHASE2CompletedINTERVENTIONAL

Enrollment

200

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

June 30, 2003

Conditions

Alzheimer's Disease

Interventions

DRUG

LY451395

Trial Locations (9)

Beverly Hills

Fresno

Boca Raton

Fort Lauderdale

Miami Beach

Boston

Oklahoma City

Tulsa

Wichita Falls

All Listed Sponsors

lead

Eli Lilly and Company

INDUSTRY

NCT00051909 - Efficacy and Safety of LY451395 in Patients With Probable Alzheimer's Disease | Biotech Hunter | Biotech Hunter